title: Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins.
abstract: Analyzing the pathways by which retinoic acid (RA) induces promyelocytic leukemia/retinoic acid receptor alpha (PML/RARalpha) catabolism in acute promyelocytic leukemia (APL), we found that, in addition to caspase-mediated PML/RARalpha cleavage, RA triggers degradation of both PML/RARalpha and RARalpha. Similarly, in non-APL cells, RA directly targeted RARalpha and RARalpha fusions to the proteasome degradation pathway. Activation of either RARalpha or RXRalpha by specific agonists induced degradation of both proteins. Conversely, a mutation in RARalpha that abolishes heterodimer formation and DNA binding, blocked both RARalpha and RXRalpha degradation. Mutations in the RARalpha DNA-binding domain or AF-2 transcriptional activation region also impaired RARalpha catabolism. Hence, our results link transcriptional activation to receptor catabolism and suggest that transcriptional up-regulation of nuclear receptors by their ligands may be a feedback mechanism allowing sustained target-gene activation.
authors.affiliation: Centre National de la Recherche Scientifique, Unité Propre de Recherche 9051, Laboratoire associé N degrees 11 du comité de Paris de la ligue nationale contre le cancer, conventionné par l'Université de Paris VII, Hôpital St. Louis, Cedex, France.
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: M
authors.initials: M
authors.lastname: Gianni
authors.forename: E
authors.initials: E
authors.lastname: Kopf
authors.forename: N
authors.initials: N
authors.lastname: Honoré
authors.forename: M
authors.initials: M
authors.lastname: Chelbi-Alix
authors.forename: M
authors.initials: M
authors.lastname: Koken
authors.forename: F
authors.initials: F
authors.lastname: Quignon
authors.forename: C
authors.initials: C
authors.lastname: Rochette-Egly
authors.forename: H
authors.initials: H
authors.lastname: de Thé
mesh_terms: D020169:Caspases / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004252:DNA Mutational Analysis; D019281:Dimerization; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism; D009097:Multienzyme Complexes / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D018168:Receptors, Retinoic Acid / Q000235:genetics / Q000378:metabolism*; D000072482:Retinoic Acid Receptor alpha; D047488:Retinoid X Receptors; D014157:Transcription Factors / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D009097:Multienzyme Complexes; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D047488:Retinoid X Receptors; D014157:Transcription Factors; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D020169:Caspases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex